Das Ziel dieser Studie war es, die Beteiligung der nichtmuskulären schweren Myosinketten an der Kontraktion der glatten Muskeln unter physiologischen Bedingungen zu untersuchen. Als Versuchsmodell wurde die Harnblase von neugeborenen Wildtyp und transgenen Mäusen verwendet, bei denen das Gen für die glattmuskelspezifischen schweren Myosinketten durch "Gene Targeting" funktionell eliminiert wurde (Knock-Out). Das Fehlen der Expression der glattmuskelspezifischen schweren Myosinketten wurde durch Elektrophorese und Immunfärbung bestätigt. Im Gegensatz dazu blieb die Expression der nichtmuskulären schweren Myosinketten unverändert. Die mechanische Analyse des glatten Muskels wurde mit intakten Muskelpräparaten aus der Harnblase durchgeführt. Das Muskelpräparat wurde in KCl-Lösung oder mit Phorbolester stimuliert. Die Aktivierung mittels depolarisierender KCl-Lösung führte bei neugeborenen Wildtyp Mäusen zuerst zu einer transienten Kontraktion (Phase 1) mit hoher Kraftentwicklung und maximaler Verkürzungsgeschwindigkeit, und danach zu einer tonischen Kontraktion (Phase 2) mit niedrigerer Kraftentwicklung und maximaler Verkürzungsgeschwindigkeit. Blasenpräparate neugeborener Knock-Out Mäuse dagegen zeigten keine Phase 1, sondern nur eine tonische Kontraktion, die mit Wildtyp Mäusen vergleichbar war. Daher scheint nichtmuskuläres Myosin an der tonischen Kontraktion des glatten Muskels beteiligt zu sein. Durch Stimulierung mit Phorbolester waren ähnliche tonische Muskelkontraktionen der Blasenpräparate sowohl bei Wildtyp als auch bei Knock-Out Mäusen zu beobachten. Vermutlich wird also das nichtmuskuläre Myosin durch Stimulierung mit Phorbolester aktiviert. Intrazelluläre Filamente wurden durch Immunfluoreszenz mit einem spezifischen Antikörper gegen nichtmuskuläre schwere Myosinketten in kultivierten primären glatten Muskelzellen untersucht. Dabei zeigten die Muskelzellen sowohl von Wildtyp als auch von Knock-Out Mäusen intrazelluläre dicke Myosinfilamente, was für die Beteiligung des nichtmuskulären Myosins an der glatten Muskelkontraktion spricht. Entsprechend wurden intrazelluläre Filamente mit einem Antikörper gegen glattmuskelspezifische schwere Myosinketten in kultivierten primären glatten Muskelzellen untersucht. Wie erwartet, konnten nur in glatten Muskelzellen von Wildtyp Mäusen intrazelluläre Filamente nachgewiesen werden, nicht aber in denen von Knock-Out Mäusen. In dieser Arbeit konnte zum ersten Mal gezeigt werden, dass nichtmuskuläres Myosin zumindest an der tonischen Kontraktion glatter Muskelzellen beteiligt sein kann. / The aim of the present study was to investigate the involvement of non-muscle myosin heavy chain in smooth muscle contraction under physiological conditions. As an experimental model urinary bladder from neonatal wild-type mice as well as from neonatal mice with disrupted smooth muscle myosin heavy chain expression was used. This animal model was established through gene targeting technology, resulting in complete elimination of the expression of smooth muscle myosin heavy chains. The lack of expression of smooth muscle myosin heavy chains was confirmed by electrophoresis and immunoblotting. On the other hand, non-muscle myosin heavy chain expression remained normal, as verified by Western blot analysis. The mechanical analysis of smooth muscle was performed with intact urinary bladder preparations, stimulated using prolonged KCl depolarization or with phorbol ester. Prolonged activation by KCl depolarization of intact bladder preparations from wild-type neonatal mice produced an initial transient state (phase 1) of high force generation and maximal shortening velocity, followed by a sustained state (phase 2) with lower force generation and maximal shortening velocity. In contrast, bladder preparations from homozygous knockout neonatal mice did not exhibit phase 1, but phase 2 could be observed, i.e. a similar isometric force and maximal shortening velocity, compared to wild-type phase 2. Thus, non-muscle myosin appears to be recruited in the sustained phase of smooth muscle contraction during prolonged KCl depolarization in the animal model used. Upon stimulation with phorbol ester a similar sustained contraction was observed in both wild-type and knockout smooth muscle preparations. Therefore, non-muscle myosin may also be recruited during phorbol ester stimulation in both wild-type and knockout muscle preparations. The participation of non-muscle myosin in smooth muscle contraction was further supported by the finding of longitudinally arranged intracellular filaments in cultivated smooth muscle cells from both wild-type and knockout mice by immunofluorescence microscopy, using a specific antibody raised against non-muscle myosin heavy chain. In a similar way, smooth muscle myosin heavy chain structures were investigated in cultivated smooth muscle cells. As expected, longitudinally arranged intracellular filamentous structures of smooth muscle myosin were observed in wild-type smooth muscle cells, but not in smooth muscle cells from knockout mice. In conclusion, in neonatal smooth muscle the initial phase of contraction elicited by KCl depolarization is generated by smooth muscle myosin heavy chain recruitment. Upon prolonged KCl depolarization non-muscle myosin is recruited in the sustained phase of contraction, as well as upon stimulation with phorbol ester. Thus, it was possible, for the first time, to verify the involvement of the non-muscle myosin in smooth muscle contraction in vivo. The results of the present study contribute to the understanding of the regulatory mechanisms of smooth muscle contraction.

No description available.

La cytokine TRAIL est un candidat anticancéreux qui induit la mort spécifique de cellules tumorales. La liaison de TRAIL à ses récepteurs (DR) permet de former le complexe DISC qui induit la mort cellulaire. La raison de la mort sélective des cellules tumorales induite par TRAIL est inconnue. Nous avons découvert des partenaires de DR: chaînes lourdes de myosine IIa, IIb (NMHCIIa, NMHCIIb), chaîne légère régulatrice de myosine (MLC2) et ß-actine. Dans les cellules tumorales, la liaison de TRAIL abroge l'interaction NMHCII/DR, et DISC est activé. Au contraire, dans les cellules normales, l'interaction NMHCII/DR persiste et l'activation de DISC est incomplète. Affaiblir l'interaction NMHCII/DR par des inhibiteurs chimiques ou diminuer NMHCIIa permet d'augmenter l'apoptose liée à TRAIL. L'interaction réduite NMHCII/DR induit des niveaux altérés de phospho-MLC2 et de kinases régulant MLC2. Nous proposons que la résistance de cellules normales à TRAIL soit basée sur l'interaction DR/cytosquelette, déficiente dans des tumeurs. NMHCII étant aussi impliqué dans l'adhésion/migration cellulaire, il serait intéressant d'étudier les fonctions de NMHCII/DISC dans le détachement cellulaire, afin de mieux comprendre la résistance à TRAIL de certains cancers. / The cytokine TRAIL is a promising cancer therapeutic candidate as it induces apoptosis selectively in transformed cells. TRAIL-induced clustering of its receptors (DR) is essential for the DISC complex formation, which induces cell death. The mechanism for TRAIL’s tumour selective effect is largely unknown. We identified the cytoskeleton proteins non-muscle myosin heavy chain IIa, IIb (NMHCIIa, NMHCIIb), myosin regulatory light chain (MLC2) and ß-actin as novel DR-interactors. An initially weak and TRAIL-induced abrogation of NMHCII/DR interaction correlated with efficient DISC formation in tumour cells. In contrast, a robust NMHCII/DR interaction that was sustained upon TRAIL stimulus was accompanied by incomplete DISC arrangement. Weakening the NMHCII/DR interaction in normal cells using chemical inhibitors enhanced TRAIL-induced apoptosis. Intriguingly, siRNA-mediated NMHCIIa- but not NMHCIIb depletion potently released TRAIL resistance in normal cells and influenced DISC composition. Reduced NMHCII/DR interaction in transformed cells was characterised by diminished MLC2 phosphorylation and altered protein expression of upstream regulatory kinases. Our results suggest that normal cell resistance to TRAIL-apoptosis is based on the interaction of cytoskeleton components with DR that is impaired upon transformation. Since NMHCII function in cell adhesion and migration, it will be interesting to study possible roles of the interaction in cell detachment and altered TRAIL sensitivity; moreover this link may provide clues as to the cause of TRAIL resistance in some cancers.

No description available.

Skeletal muscle dysfunction in chronic obstructive pulmonary disease (COPD) is a condition in which peripheral skeletal muscle undergoes myopathic changes which impair muscle function, limit physical performance, and can lead to significant disability. While the etiology of the dysfunction is unknown, this study was conducted to test the hypothesis that chronic hypoxemia leads to alterations in oxygen transport and muscle function. A primary objective was to validate elastase-induced emphysema in rats as an animal model of skeletal muscle dysfunction in COPD.Arterial blood gases were used to determine the severity of hypoxemia and sodium dodecyl sulfate- polyacrylamide gel electrophoresis was used to determine the proportions of myosin heavy chain isoforms I, IIa, IIx, and IIb. Measures of microvascular oxygenation and blood flow in the spinotrapezius muscle allowed for determination of both convective and diffusive oxygen supply to the muscle, as well as calculation of muscle oxygen consumption at rest and during electrically stimulated three-minute muscle contractions. Muscle performance measures included peak force, force-time integral, and fatigue index. Due to a presumed rat respiratory virus, which likely resulted in the control group being nearly as hypoxemic as the elastase-induced emphysema group, this study was not able to definitively test the hypothesis that chronic hypoxemia leads to both a diminished supply and demand of oxygen in skeletal muscle. Although many of the results of the present study were not statistically significant, they exhibited consistent trends over time and are likely of physiological significance. All measures of muscle performance were lower in the emphysema group. In addition, spinotrapezius muscle oxygen consumption and blood flow were lower in the emphysema group. The addition of supplemental oxygen during isolated, small-muscle mass exercise did increase the force-time integral by ~18% in both groups, suggesting that muscle work in these hypoxemic animals may be limited by oxygen supply. Thus, the data on muscle fiber type, oxygen consumption and muscle performance suggest that elastase-induced emphysema in rats leads to a similar skeletal muscle dysfunction that is observed in humans with COPD, and indicates that it is a valid animal model of skeletal muscle dysfunction in COPD.

Made available in DSpace on 2014-06-11T19:31:01Z (GMT). No. of bitstreams: 0 Previous issue date: 2009-02-27Bitstream added on 2014-06-13T19:19:53Z : No. of bitstreams: 1 duarte_dr_dr_botfm.pdf: 365312 bytes, checksum: 5b54817ed6d69d3fe0e8673385f863f0 (MD5) / Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) / O hábito de fumar apresenta importante impacto na saúde da população. A associação entre fumo e doença cardiovascular tem sido amplamente explorada em relação à aterosclerose. Recentemente, evidências clínicas e experimentais sugerem que a exposição ao cigarro pode modular o processo de remodelação ventricular. O objetivo desse estudo foi avaliar o papel do inibidor da enzima conversora da angiotensina no processo de remodelação induzido pela exposição à fumaça do cigarro. Ratos Wistar foram distribuídos em três grupos: 1) grupo controle (C, n=8); 2) grupo exposto à fumaça do cigarro (EFC, n=8); 3) grupo exposto à fumaça do cigarro e recebendo 20 mg/kg/dia de lisinopril (EFC-LIS, n=8). Após dois meses os animais foram submetidos ao estudo funcional, morfométrico, e bioquímico. Para a análise estatística foi utilizado o teste de variância ANOVA complementado por Holm-Sidak, o teste Kruskal-Wallis complementado por Tukey e o teste Mann-Whitney. O nível de significância foi 5%. A pressão sistólica caudal foi menor no grupo EFC-LIS (C = 116 ± 27, EFC = 126 ± 16, EFC-LIS = 89 ± 12 mmHg; p = 0,003) em relação aos grupos C e EFC; o grupo EFC apresentou maior valor do diâmetro sistólico do ventrículo esquerdo, corrigido pelo peso (C = 8,25 ± 2,16, EFC = 11,76 ± 1,20, EFC-LIS = 9,27 ± 2,00 mm/kg; p = 0,003), em comparação aos grupos C e EFC-LIS; o diâmetro diastólico do ventrículo esquerdo ajustado pelo peso foi maior nos grupos EFC e EFC-LIS... / The habit of smoking has important impact on population health. The association between tobacco and cardiovascular disease has been widely explored in relation to atherosclerosis. Recently, clinical and experimental evidences suggest that the exposure to tobacco smoke can modulate the process of ventricular remodeling. The objective of that study was to evaluate the role of the angiotensin-converting enzyme inhibitor on cardiac remodeling induced by tobacco smoke exposure. Wistar rats were allocated in three groups: 1) group control (C, n=8); 2) group exposed to tobacco smoke (EFC, n=8); 3) group exposed to tobacco smoke and treated with lisinopril 20mg/kg/day (EFC-LIS, n=8). After two months the animals were submitted to the functional study, morphometric, and biochemical. For the statistical analysis was used the ANOVA test of variance complemented by Holm-Sidak, the test Kruskal-Wallis complemented by Tukey and the test the Mann-Whitney. The significance level was 5%. Results: the caudal systolic pressure was smaller in the group EFC-LIS (C = 116 ± 27, EFC = 126 ± 16, EFC-LIS = 89 ± 12 mmHg; p = 0,003) in relation to the groups C and EFC; the group EFC presented higher value of the systolic diameter of the left ventricle, corrected by body weight (BW) (C = 8,25 ± 2,16, EFC = 11,76 ± 1,20, EFC-LIS = 9,27 ± 2,00 mm/kg; p = 0,003), in comparison with the groups C and EFC-LIS; the diastolic diameter of the left ventricle, adjusted by BW was higher in the groups EFC e EFC-LIS (C = 18,42 ± 3,57, EFC = 22,94 ± 1,98, EFC-LIS = 22,05 ± 1,30 mm/kg; p = 0,003); the relationship EPP/DDVE was smaller in the group EFC-LIS in relation to the control (C = 0,20 (0,18-0,23), EFC = 0,15 (0,14-0,18), EFC-LIS = 0,14 (0,14-0,18); p = 0,026). The group EFC presented smaller ejection fraction... (Complete abstract click electronic access below)

The tumour suppressor protein p16INK4a (p16) is a cyclin-dependent kinase (CDK) inhibitor that plays a key role in the regulation of the cell cycle by controlling the progression of cells through the G1 to S phase transition. Dysregulation of the protein through deletion, silencing or mutation of the gene encoding p16 is implicated in a range of different cancers including melanoma, cervical and oesophageal to name a few. p16 is composed of four ankyrin repeats and it has a very low thermodynamic and kinetic stability and rapidly unfolds even in the absence of denaturants. This low stability means that the protein is highly vulnerable to point mutations, which can result in functional inactivation through a range of different mechanisms such as deletion of key binding contacts, disruption of secondary or tertiary structure and consequent destabilisation leading to unfolding or aggregation. Heavy-chain antibodies are a unique form of antibody devoid of light chains found in the serum of the Camelid family (camels and llamas). Despite the absence of light chains, heavy-chain antibodies have evolved to complement traditional antibodies and retain the full binding capacity seen in canonical IgG antibodies. The single variable domain, known as a nanobody, is, at 15 kDa, the smallest antigen binding fragment, a tenth the size of a standard IgG antibody. The small size and relative ease of production, coupled with an unusually high stability, makes nanobodies useful tools as biological reagents, crystallography chaperones and therapeutics. The research contained within this PhD looks at the development of nanobodies to target p16. By leveraging the high stability of selected nanobodies, the aim was to obtain binders that could stabilise and reactivate a range of unstable cancer-associated mutants. The initial stages of the project focused on generating and optimising the expression and purification of p16 constructs prior to immunisation of animals to raise nanobodies. A high-throughput approach was taken to generate forty-five different p16 constructs with a range of different solubility and purification tags. These constructs were assessed in a multi-factorial expression screen, which resulted in the identification of a p16 construct with a ten-fold improvement in soluble expression levels compared with previous studies. A range of biophysical techniques, including circular dichroism and chemical denaturation, were performed to characterise this protein fully prior to immunisation. The second part of this project utilised a phage display library of two immune nanobody libraries generated against p16 and a p16 variant stabilised by previously published second-site mutations. This process yielded a large number of diverse nanobodies. Biophysical characterisation of these nanobodies was first performed, and they were found to have a range of chemical and thermal stabilities. Assays were then developed to test the ability of the nanobodies to stabilise p16. Two nanobodies were found to dramatically stabilise wild-type p16, with an increase in stability of approximately 44 % and 60 %, respectively. Furthermore, these nanobodies were also able to stabilise a subset of cancer-associated point mutants. Although there are NMR structures of p16, as well as a crystal structure of p16 bound to CDK6, the resolution of is very low, most likely due to the high backbone flexibility of p16. The last part of the project aimed to obtain a higher-resolution structure of p16 by using the two stabilising nanobodies as crystallisation chaperones. The more stabilising of the two nanobodies resulted in crystals that diffracted to a resolution of less than 2 $\AA$, a significant improvement compared with the previously published structure. In conclusion, a number of nanobodies were generated against tumour-associated p16 and shown to be capable of stabilising p16, allowing structure determination to high resolution and restoration of the stability of cancer-associated mutants to wild-type levels. In the project, a range of different approaches for nanobody production were explored, and these will be important for future applications. Moreover, the crystal structure of the p16-nanobody complex showed that the nanobody binds on the opposite face of p16, to the face involved in binding to CDKs; thus, this nanobody could potentially be exploited as a pharmacological chaperone to stabilise and restore the activity of cancer-associated mutant p16 in the cell.

<p>The combination of a severe systemic illness, corticosteroids, and neuromuscular blocking agents in patients on the mechanical ventilator often results in a condition known as Acute Quadriplegic Myopathy (AQM). While severe weakness of all spinal nerve innervated muscles is known to be a significant clinical characteristic of the disease, this symptom is typically not recognized until the disease has progressed to an advanced stage. End result effects have been classified, which include the loss of the thick filament, or myosin heavy chain, an in-excitable muscle membrane, and an up-regulation of protein degradation; however, there is little known about the acute stage of AQM. This project has focused on understanding the underlying mechanisms of AQM, specifically in regard to protein synthesis, both at the mRNA and nuclear transcription levels. To study the early stages of the disease two animal models have been developed: rat and pig. Further, we have examined AQM muscle tissue, to investigate the similarities of our animal models to patients, as well as to study the recovery process. Particular interest was directed on the myofibrillar proteins myosin (MyHC) and actin, as they are the primary proteins involved in muscle contraction, as well as the myosin associated proteins, myosin binding protein C and H. </p><p>At the mRNA level, MyHC and actin are both down-regulated in response to AQM. The myosin binding proteins are affected differently, with H protein increasing during severe atrophy and C protein either being slightly down-regulated or unchanged. Nuclear transcription factors were also affected, with such factors as MuRF1 and MAFbx up-regulated. </p><p>Thus far results have shown that protein synthesis is altered in AQM and largely contributes to both the development and recovery of the disease. The pathways of protein synthesis may prove to be an ideal target for the prevention of AQM and/or symptom alleviation.</p>

<p>Malt lymphoma is a malignant disease that can arise in a variety of extra nodal sites. Previous studies indicate that tumour arise from more mature B-cells.</p><p>Our purpose was to examine the presence of clonality and somatic hypermutation of immunoglobulin (IgVн) of MALT lymphomas.</p><p>Paraffin-embedded tumour samples from13 MALT lymphoma were subjected to rearrangement analysis, by using PCR, heteroduplex gels and sequence analysis.</p><p>Successful amplification was seen in 10/13 cases and sequences of IgVн genes were obtained in 6/13, all of them were mutated. The percentage of mutation compared to germline sequences was 1,1% to 8,6% monoclonal rearrangemang. It was demonstrated that 5 of 7 clones were derived from the Vн3 family, 2 from Vн1 and 1 from the Vн 4 family.</p>

Skeletal muscle is a heterogeneous, multinucleated, post-mitotic tissue that contains many functionally diverse fibre types that are capable of adjusting their phenotypic properties in response to altered contractile demands. This plasticity, or adaptability of skeletal muscle is largely dictated by variations in motoneuron firing patterns. For example, in response to increased tonic firing of slow motoneurons, which occurs during bouts of endurance training or chronic low-frequency stimulation (CLFS), skeletal muscle adapts by transforming from a faster to a slower phenotypic profile. CLFS is an animal model of endurance training that induces fast-to-slow fibre type transformations in the absence of fibre injury in the rat. The underlying signaling mechanisms regulating this fast-to-slow fibre type transformation, however, remain to be fully elucidated. It has been suggested that myogenic stem cells, termed satellite cells, may regulate and/or facilitate this transformational process. Therefore, the signaling mechanisms involved in CLFS-induced satellite cell activation as well as the role satellite cells may play in CLFS-induced skeletal muscle adaptation were investigated in rat. A pharmacological inhibitor of nitric oxide (NO) synthase, Nω-nitro-L-arginine methyl ester, was used to investigate CLFS-induced satellite cell activation in the absence of endogenous NO production. Results suggest that NO is required for early CLFS-induced satellite cell activation, but a yet-to-be defined pathway exists that is able to fully compensate in the absence of prolonged NO production. A novel method of satellite cell ablation (i.e. weekly focal γ-irradiation application) was used to investigate CLFS-induced skeletal muscle adaptation in the absence of a viable satellite cell population. Myosin heavy chain (MHC), an important structural and regulatory protein component of the contractile apparatus, was used as a cellular marker of the adaptive response to CLFS. Findings suggest that satellite cell activity may be required for early fast-to-slow MHC-based transformations to occur at the protein level without delay in the fast fibre population, and may also play an obligatory role in the final transformation from fast type IIA to slow type I fibres. Interestingly, additional results show that NO appears to be a key mediator of MHC isoform gene expression during CLFS-induced fast-to-slow fibre type transformations.